MoneyWorks4Me

Jubilant Pharmova - Quaterly Results

27 Oct 2023 Evaluate
The sales declined to Rs. 1863.00 millions for the September 2023 quarter as compared to Rs. 2229.00 millions during the corresponding quarter last year.The Net Loss for the quarter ended September 2023 is Rs. -4.00 millions as compared to Net Profit of Rs. 918.00 millions of corresponding quarter ended September 2022A decline of 192.00 millions was observed in the OP in the quarter ended September 2023 from 1134.00 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 1863.00 2229.00 -16.42 4037.00 4275.00 -5.57 8101.20 7257.30 11.63
Other Income 184.00 1062.00 -82.67 343.00 1164.00 -70.53 1378.90 1261.60 9.30
PBIDT 192.00 1134.00 -83.07 393.00 1193.00 -67.06 1411.10 1326.20 6.40
Interest 71.00 41.00 73.17 135.00 73.00 84.93 185.20 109.90 68.52
PBDT 121.00 1093.00 -88.93 258.00 1120.00 -76.96 1225.90 1216.30 0.79
Depreciation 119.00 111.00 7.21 233.00 203.00 14.78 432.50 369.10 17.18
PBT 2.00 982.00 -99.80 25.00 917.00 -97.27 793.40 847.20 -6.35
TAX 6.00 64.00 -90.63 10.00 51.00 -80.39 294.60 42.30 596.45
Deferred Tax 6.00 -80.00 -107.50 6.00 -93.00 -106.45 156.40 -100.50 -255.62
PAT -4.00 918.00 -100.44 15.00 866.00 -98.27 498.80 804.90 -38.03
Equity 159.00 159.00 0.00 159.00 159.00 0.00 159.30 159.30 0.00
PBIDTM(%) 10.31 50.87 -79.74 9.73 27.91 -65.12 17.42 18.27 -4.68
Peers
Company Name CMP
Sun Pharma. Inds. 1835.50
Dr. Reddys Labs. 1171.10
Cipla 1371.45
Lupin 2144.70
Zydus Lifesciences 1153.00
View more..